A generic strategy for pharmacological caging of growth factors for tissue engineering†

Maria Karlsson,a,b Philipp S. Lienemann,c,d Natallia Sprossmann,a,e Katharina Heilmann,e Tilman Brummer,e,f,g Matthias P. Lutolf,d Martin Ehrbarc and Wilfried Weber*a,b,f

The caging of small molecules has revolutionized biological research by providing a means to regulate a wide range of processes. Here we report on a generic pharmacological method to cage proteins in a similar fashion. The present approach is of value in both fundamental and applied research, e.g. in tissue engineering.

The trapping of biological compounds in cages and the subsequent controlled uncaging of them at the site of interest allows for a nearly instantaneous manipulation of the bioactive compound concentration. The caging of signaling molecules, such as second messengers (e.g. calcium and inositol triphosphate), neurotransmitters (e.g. glutamate), and nucleotides (e.g. ATP and ADP), has revolutionized biological research by providing a means to spatiotemporally regulate and monitor a wide range of cellular processes. Caging based on chemical modification of the molecule using a photo-removable protective group has been successfully applied to a multitude of small signaling molecules. The same strategy has also been applied to chemically synthesizable peptides, however, it is in most cases not compatible with large proteins. Instead, large proteins require a tailored caging procedure for each individual protein of interest, and the caging is often complicated due to difficulties in achieving site-specific chemical modification. Considering the wide range of biological signaling processes relying on non-chemically synthesizable proteins, there is a demand for a method enabling the caging of these in a generic manner. Such a method would be an excellent tool for the manipulation of protein-regulated processes, e.g. in developmental biology and tissue engineering. In order to realize this, two separate parts are required: a cage able to trap any protein of choice, and a generically applicable protocol for producing cage-compatible cargo proteins with high yield.

We have developed a generic system enabling pharmacological caging and uncaging of arbitrary proteins equipped with an immunoglobulin (IgG) Fc-tag. The cage was formed by covalently coupling novobiocin to an epoxy-activated agarose matrix via a nucleophilic addition reaction. The anchoring of the cargo protein to the cage was realized using an adaptor protein consisting of the novobiocin-binding domain of the bacterial protein gysunubit B (GyrB) fused to the IgG-binding domain ZZ derived from Staphylococcus aureus protein A (Fig. 1a). The adaptor protein binds to the novobiocin on the cage through its GyrB domain, allowing the ZZ-domain of the adaptor protein to anchor the cargo protein by binding to the Fc-domain. Upon the administration of free novobiocin at pharmacologically relevant concentrations, binding between the adaptor protein and the cargo is competitively inhibited, which results in the uncaging of the cargo protein. The rapid uncaging of the protein produces a step function-like release of the bioactive compound, which enables precise temporal regulation of the target process (Fig. 1a).

The cage was characterized in cell culture medium using an Fc-tagged version of the human placental secreted alkaline phosphatase (SEAPc) as a human model glycoprotein. Caged SEAPc was incubated with various concentrations of novobiocin and the amount of uncaged SEAPc was monitored by measuring the enzymatic activity of the protein over a time period of 5 hours (Fig. 1b). Without novobiocin, only a low level of unspecific uncaging occurs. The addition of novobiocin, either immediately or after two hours, triggered rapid uncaging of the protein. The final activity depended on the novobiocin concentration. A maximum uncaged protein fraction of 70% was measured at novobiocin concentrations equal to or greater than 60 μM. The caging efficiency was determined to be 35 ng of SEAPc per mg of the cage, of which 4.2% are non-specifically adsorbed.
Growth factor-controlled processes are of fundamental importance in both developmental biology and tissue engineering. One out of the many potential applications of our generic system is the caging of growth factors, which would enable the regulation and thus analysis and engineering of the numerous signaling processes governed by these proteins. To achieve this aim a production protocol applicable to a wide range of growth factors is required in addition to the cage. In order to efficiently engineer an arbitrary growth factor for incorporation into the cage, we devised a generic gene assembly and protein production platform (see ESI†). The growth factor platform was validated for the manufacturing of cage-compatible variants of the vascular endothelial growth factor 121 (VEGF<sub>Fc</sub>), the insulin-like growth factor 1 (IGF1<sub>Fc</sub>), and the platelet-derived growth factor subunit B (PDGF-BB<sub>Fc</sub>), resulting in a protein yield of 950 ng ml<sup>-1</sup>, 1170 ng ml<sup>-1</sup> and 400 ng ml<sup>-1</sup>, respectively. Although the protein expression protocol was not explicitly optimized for each of the growth factors, the production yield was significantly improved for all of them (ESI† Fig. S1c). This suggests that the optimized production protocol can be generally applied to increase the expression yield of cage-compatible Fc-tagged recombinant proteins.

In order to ensure that the growth factors remain bioactive when equipped with an Fc-tag, bioactivity assays for all produced growth factors were performed. The bioactivity of VEGF<sub>Fc</sub> was confirmed by assessing the VEGF<sub>Fc</sub>-induced proliferation of human umbilical vein endothelial cells (HUVECs, Fig. 2a, ref. 8). The bioactivity of IGF1<sub>Fc</sub> was evaluated by stimulating mouse embryonic fibroblasts (MEFs) with 50 ng ml<sup>-1</sup> IGF1<sub>Fc</sub> during various time periods resulting in pathway activation as demonstrated by the phosphorylation of ERK and AKT as well as the induction of the immediate early gene product Egr-1 (Fig. 2b, ref. 9 and 10). The bioactivity of PDGF-BB<sub>Fc</sub> was demonstrated using human embryonic kidney cells (HEK-293T) transiently transfected with a PDGF signaling pathway coupled to a firefly luciferase output promoter (PDGF-BB receptor, pPDGFR-BB; GAL4-Erk1 fusion protein, pF2-A-Erk1; GAL4-responsive firefly luciferase reporter, pFR-Luc). As an internal control, the constitutive renilla luciferase expression vector (pGL4.75) was included in the transfection mix. The cells were incubated for 48 h in the presence of the indicated PDGF-BB<sub>Fc</sub> concentrations prior to quantification of luciferase activity. The PDGF-responsive firefly luciferase activity was normalized to the renilla luciferase activity. Data indicate the mean and the standard deviation of triplicate experiments.
A movie illustrating the effect of uncaged PDGF-BBcF on the migration of MSCs can be found in the ESIT (Video S1).

We have demonstrated a generic approach for the caging and uncaging of arbitrary proteins. The cage along with optimized growth factor production provides a versatile platform for exploring a variety of biological signaling processes through the precisely controlled uncaging of a bioactive compound. The controlled migration of MSCs through regulated uncaging of growth factors illustrates how our system can be used to precisely direct cellular behavior. Considering the tremendous success of caged small signaling molecules in biological research, we believe that the present method will be a valuable asset, not only in developmental biology, tissue engineering and anti-tumor therapy, where the understanding and manipulation of growth factor-controlled signaling processes is of fundamental importance, but also for the regulation of a wide range of additional biological processes of interest in fundamental and applied research.

We thank Aida Kurmanaviciene for technical assistance and Oleg Semenov for help with MSC isolation. This work was supported by the Swiss National Science Foundation (no. CR3213-125426/1 and 310000-116240), the European Union within the framework of the “INTERREG IV Upper Rhine program (project A20), the Initiating and Networking Fund (IVF) of the Helmholtz Association within the Helmholtz Initiative on Synthetic Biology (SO-078) and the excellence initiative of the German Federal and State Governments (EXC-294).

Notes and references